Global Nervous System Cancer Treatment Market: Overview
Central nervous system (CNS) cancer tumor initiates when the cells in the spinal cord or the brain undergo uncontrollable growth forming a mass. CNS tumor can be benign or malignant. Types of tumors associated with the brain are glioblastoma, meningioma, astrocytoma, brain stem, glioma, ependymoma, germ cell tumor, and medulloblastoma. Diagnostic tests performed for identification of the type of tumor include biopsy and imaging such as X-ray, MRI (magnetic resonance imaging), and CT scan (computed tomography). Generally, surgery is considered a primary treatment of the central nervous system cancer tumor. Chemotherapy and radiotherapy can be used to control the growth of new, cancerous tumors. According to Centers for Disease Control & Prevention (CDC), in 2011, approximately 22,000 patients in the U.S. were identified with primary malignant tumors in the brain and the spinal cord, out of which gliomas accounted for the maximum rate of incidence. As for the treatment of glioblastoma, there are several restraints and challenges such as resistance of glioblastoma to DNA-modifying agents, migration of malignant cells into the adjacent brain tissues (which increases the complexity of the surgery), and the current FDA-approved treatments that may cause neurotoxicity in patients. Thus, as available treatment options lack in efficiency, the mortality rate of glioblastoma is characterized by rapid progression. The disease has poor survival rate with only 8.7% of the patients surviving for more than two years after diagnosis.
Global Nervous System Cancer Treatment Market: Drivers and Restraints
Increasing prevalence, awareness, and advancements in treatment and the variety of treatments available drive the market for central nervous system cancer treatment. A large number of therapeutic drugs and devices for central nervous system cancer are in pipeline. They are expected to receive FDA approvals for conducting the clinical trials. FDA-approved drugs currently available in the market are temozolomide (Temodar, Temodal, and Temcad), bevacizumab (Avastin), and carmustine wafers (BiCNU). Ongoing research and availability of a wide pipeline of drugs are expected to boost the central nervous system cancer treatment market during the forecast period. Treatment options for the central nervous system cancer are costlier. Hence, high prices of chemotherapy agents for the treatment of CNS cancer are likely to hinder the market during the forecast period. Affordable pricing policies of governments and patient support programs are expected to augment the central nervous system cancer treatment market from 2017 to 2025. At present, availability and cost of treatment are factors restraining the central nervous system cancer treatment market.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Biospace
